샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795392

세계의 백신 연구 시장

Vaccine Research
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 172 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

백신 연구 세계 시장은 2030년까지 738억 달러에 달할 전망

2024년에 394억 달러로 추정되는 백신 연구 세계 시장은 2024년부터 2030년까지 CAGR 11.0%로 성장하여 2030년에는 738억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석하고 있는 부문 중 하나인 공적 백신 연구는 CAGR 12.3%를 기록하며 분석 기간 종료시에는 518억 달러에 달할 것으로 예측됩니다. 민간 백신 연구 분야의 성장률은 분석 기간 동안 CAGR 8.3%로 추정됩니다.

미국 시장은 104억 달러, 중국은 CAGR 10.0%로 성장할 것으로 예측

미국의 백신 연구 시장은 2024년에 104억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 113억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 10.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 9.9%와 8.9%로 예측됩니다. 유럽에서는 독일이 CAGR 약 8.5%로 성장할 것으로 예측됩니다.

세계의 백신 연구 시장 - 주요 동향과 촉진요인 정리

백신 연구가 세계 보건 및 바이오메디컬 과학의 전략적 우선순위인 이유는 무엇일까?

백신 연구는 현대 생물 의학의 중요한 축으로 공중 보건 성과, 전염병 대비, 전염병에 대한 세계 대응에 직접적인 영향을 미치고 있습니다. 전 세계가 COVID-19 팬데믹의 엄청난 영향으로부터 회복하는 과정에서 백신 연구에 대한 관심이 높아지고 있으며, 기존 병원체와 신종 병원체 모두에 대응하기 위한 과학 중심의 민첩한 기술 혁신의 필요성이 강조되고 있습니다. 역사적으로 백신 개발은 시간과 노력이 많이 소요되는 과정으로, 제품을 시장에 출시하기까지 10년 이상 걸리는 경우가 많았습니다. 그러나 최근 세계 보건 위기의 긴급성은 일정을 앞당기고, 전례 없는 자금을 동원하고, 정부, 학계, 제약 업계 간의 협력 체제를 촉진했습니다. 이러한 발전으로 백신 연구는 반응적 접근에서 적극적 접근으로 승화되었습니다. 오늘날 백신은 독감, 홍역, HIV 등 감염성 질환뿐만 아니라 암, 자가면역질환, 중독증 등 비감염성 질환에 대해서도 연구되고 있습니다. 전 세계가 상호연결되고 도시화가 진행됨에 따라 병원균의 급속한 전파에 따른 위험이 증가하고 있으며, 백신은 질병 예방에 있어 가장 비용 효율적이고 강력한 수단 중 하나가 되었습니다. 또한, 세계 건강 형평성 목표는 저소득 지역을 위한 저렴하고 안정적이며 확장 가능한 백신의 개발에 점점 더 의존하고 있습니다. 따라서 백신 연구는 더 이상 단순한 과학적, 임상적 사업이 아니라 건강 안보, 경제 회복력, 사회 안정을 지탱하는 전 세계의 시급한 과제입니다.

과학기술의 발전은 백신 연구 상황을 어떻게 변화시키고 있는가?

백신 연구 상황은 질병 예방 가능성의 한계를 확장하는 과학적, 기술적 혁신의 물결로 인해 변화하고 있습니다. 가장 획기적인 발전 중 하나는 mRNA 백신 플랫폼의 등장으로, COVID-19 사태에서 그 효과가 입증되었으며, 현재 다른 감염성 및 비감염성 질환에 대한 연구도 진행되고 있습니다. 이 플랫폼은 신속한 설계 및 제조, 새로운 균주에 대한 적응성, 확장 가능한 제조가 가능하여 팬데믹 대응에 이상적입니다. 또한, 바이러스 벡터 기술, 재조합 단백질 서브유닛, 나노입자 기반 전달 시스템을 통해 연구자들은 부작용이 적고 보다 표적화되고 효과적인 백신을 개발할 수 있게 되었습니다. 구조 생물학 및 계산 모델링을 통해 과학자들은 전례 없는 정밀도로 항원을 설계할 수 있게 되어 면역원성을 향상시키고 개발 위험을 줄일 수 있게 되었습니다. 보조제의 기술 혁신 또한 특히 노약자나 면역결핍자 등의 집단에서 면역반응을 향상시키고 있습니다. 유전체 및 단백질체학 기술은 병원체의 진화와 숙주와 병원체의 상호 작용에 대한 깊은 인사이트를 제공하여 차세대 백신 설계의 지침이 되고 있습니다. 인공지능과 머신러닝은 백신 표적 식별, 효능 예측, 면역 반응 시뮬레이션을 위해 초기 단계의 연구에 통합되고 있습니다. 하이스루풋 스크리닝, 자동화, 합성생물학은 개발 기간과 제조 비용을 절감하고 있습니다. 이러한 기술 혁신은 백신의 성능을 향상시킬 뿐만 아니라 맞춤형 백신, 다가 백신, 그리고 다양한 관련 병원체를 방어할 수 있는 만능 백신의 가능성을 열어줍니다.

전 세계 백신 연구를 추진하는 기관과 지역은?

전 세계 백신 연구 노력은 주요 기업, 생명공학 기업, 학술 연구 센터, 정부 기관의 네트워크에 의해 추진되고 있습니다. 북미에서는 국립보건원(NIH), 질병통제예방센터(CDC), 다수의 대학 등의 기관이 화이자, 모더나, 존슨앤드존슨과 같은 민간기업과 협력하여 백신 개발 노력을 수년간 주도해 왔습니다. 유럽도 강력한 허브이며, 유럽의약품청(EMA), 옥스퍼드대학교, 다수의 독일계 바이오테크놀러지 기업 등의 기관이 새로운 백신 플랫폼 및 제조 공정 연구에 기여하고 있습니다. 아시아에서는 중국과 인도가 백신 연구개발 역량을 빠르게 확장하고 있으며, 중국과학원, 바랏 바이오텍, 인도 혈청연구소 등의 기관이 대규모 임상시험과 세계 백신 유통을 주도하고 있습니다. 일본과 한국도 만성질환 및 희귀질환을 위한 차세대 백신 등 바이오의약품 혁신에 많은 투자를 하고 있습니다. Gavi, CEPI(Coalition for Epidemic Preparedness Innovations), 세계보건기구(WHO)와 같은 세계 연합은 국제적인 연구 노력의 조정, 저소득 국가에서의 임상시험 자금 지원, 공평한 백신 접근성 보장에 있어 중심적인 역할을 하고 있습니다. 역할을 하고 있습니다. 또한, 다국적 이니셔티브와 빌 & 멜린다 게이츠 재단과 같은 자선 재단을 통해 자금을 지원하는 공동 연구 프로젝트는 지역 간 격차를 해소하고 개발 일정을 앞당기는 데 도움을 주고 있습니다. 이러한 부문별, 국가 간 파트너십은 지식과 자원을 공유하고 세계 전략적 협력을 통해 백신 연구의 이익을 확보하는 데 필수적입니다.

백신 연구 시장의 성장과 투자를 촉진하는 요인은 무엇인가?

백신 연구 시장의 성장은 공중 보건의 필요, 상업적 기회, 기술적 준비, 세계 정책 이니셔티브의 수렴에 의해 이루어집니다. 가장 두드러진 원동력 중 하나는 감염증의 발생 빈도와 심각성의 증가이며, 이로 인해 신속하게 개발 및 배포할 수 있는 새로운 백신에 대한 시급성이 지속적으로 증가하고 있습니다. 미래의 팬데믹(세계적 대유행)과 한때 통제 하에 있다고 여겨졌던 질병의 재유행이 예상됨에 따라 각국 정부와 국제보건기구는 국가 및 국제적인 대비 계획의 중요한 요소로 백신 기술 혁신에 대한 투자를 독려하고 있습니다. 동시에 인구 고령화, 도시화, 세계 여행과 같은 인구통계학적 추세는 감염에 취약한 인구를 확대하고 있으며, 보다 광범위한 예방접종 전략의 필요성이 커지고 있습니다. 또한, 항균제 내성균의 증가로 항생제 의존도를 낮추기 위한 백신과 같은 예방적 해결책에 대한 모색도 강화되고 있습니다. 상업적 측면에서는 블록버스터 백신의 성공이 백신 연구개발의 경제적 가능성을 입증하고, 벤처 캐피털, 제약사와의 제휴, 기관투자자의 자금을 이 분야로 끌어들이고 있습니다. mRNA 플랫폼과 확장 가능한 바이오 제조 기술 검증과 같은 기술적 진보는 투자 위험을 줄이고 신속한 제품 개발을 촉진했습니다. 또한, 신속한 규제 경로, 선진적인 시장 약속, 자금 지원 인센티브와 같은 정책적 지원은 혁신을 더욱 촉진하고 있습니다. 이러한 복합적인 힘은 공중보건의 성과뿐만 아니라 생물의학 및 세계 헬스케어 시스템의 미래에도 중요한 역할을 하는 견고하고 빠르게 성장하는 백신 연구 시장을 형성하고 있습니다.

부문

유형(공적 백신 연구, 민간 백신 연구), 연령층(소아 연령층, 성인 연령층)

조사 대상 기업 사례

  • AstraZeneca
  • Bavarian Nordic
  • BioNTech SE
  • Bharat Biotech
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline(GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson(Janssen Pharmaceuticals)
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Valneva SE

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.08.28

Global Vaccine Research Market to Reach US$73.8 Billion by 2030

The global market for Vaccine Research estimated at US$39.4 Billion in the year 2024, is expected to reach US$73.8 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Public Vaccine Research, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$51.8 Billion by the end of the analysis period. Growth in the Private Vaccine Research segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Vaccine Research market in the U.S. is estimated at US$10.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Vaccine Research Market - Key Trends & Drivers Summarized

Why Is Vaccine Research a Strategic Priority in Global Health and Biomedical Science?

Vaccine research has become a critical pillar of modern biomedical science, directly influencing public health outcomes, pandemic preparedness, and the global response to infectious diseases. With the world still recovering from the profound impacts of the COVID-19 pandemic, the spotlight on vaccine research has intensified, underscoring the need for agile, science-driven innovation to counter both existing and emerging pathogens. Historically, vaccine development was a slow and labor-intensive process, often taking a decade or more to bring a product to market. However, the urgency of recent global health crises has accelerated timelines, mobilized unprecedented funding, and fostered collaborative frameworks between governments, academia, and the pharmaceutical industry. These developments have elevated vaccine research from a reactive to a proactive endeavor. Today, vaccines are being investigated not only for infectious diseases like influenza, measles, and HIV, but also for non-infectious conditions such as cancer, autoimmune diseases, and addiction. As the world becomes more interconnected and urbanized, the risks associated with rapid pathogen transmission are growing, making vaccines one of the most cost-effective and powerful tools in disease prevention. Moreover, global health equity goals are increasingly dependent on the development of affordable, stable, and scalable vaccines for low-income regions. Vaccine research is therefore no longer just a scientific or clinical undertaking but a global imperative that supports health security, economic resilience, and social stability.

How Are Scientific and Technological Advances Transforming the Vaccine Research Landscape?

The vaccine research landscape is undergoing a transformative shift, driven by a wave of scientific and technological breakthroughs that are expanding the limits of what is possible in disease prevention. One of the most revolutionary advancements is the rise of mRNA vaccine platforms, which proved their efficacy during the COVID-19 crisis and are now being explored for other infectious and non-infectious diseases. This platform allows for rapid design and production, adaptability to new strains, and scalable manufacturing, making it ideal for pandemic response. Additionally, viral vector technologies, recombinant protein subunits, and nanoparticle-based delivery systems are enabling researchers to develop more targeted and effective vaccines with fewer side effects. Structural biology and computational modeling are allowing scientists to design antigens with unprecedented precision, increasing immunogenicity and reducing development risks. Adjuvant innovation is also enhancing immune responses, especially in populations such as the elderly or immunocompromised. Genomic and proteomic technologies are providing deeper insights into pathogen evolution and host-pathogen interactions, guiding the design of next-generation vaccines. Artificial intelligence and machine learning are being integrated into early-stage research to identify vaccine targets, predict efficacy, and simulate immune responses. High-throughput screening, automation, and synthetic biology are reducing development timelines and production costs. Together, these innovations are not only improving vaccine performance but also opening the door to custom, multivalent, and even universal vaccines capable of protecting against a broad array of related pathogens.

Which Institutions and Geographies Are Driving Global Vaccine Research Efforts?

Global vaccine research efforts are being powered by a network of leading institutions, biotech companies, academic research centers, and government bodies that collectively span the globe. In North America, organizations such as the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and numerous universities have long led vaccine development efforts in collaboration with private firms like Pfizer, Moderna, and Johnson & Johnson. Europe is also a strong hub, with institutions such as the European Medicines Agency (EMA), the University of Oxford, and numerous German biotech companies contributing to research on novel vaccine platforms and manufacturing processes. In Asia, China and India have rapidly expanded their vaccine R&D capabilities, with institutions like the Chinese Academy of Sciences, Bharat Biotech, and the Serum Institute of India leading large-scale clinical trials and global vaccine distribution. Japan and South Korea are also investing heavily in biopharmaceutical innovation, including next-generation vaccines for chronic and rare diseases. Global coalitions such as Gavi, CEPI (Coalition for Epidemic Preparedness Innovations), and the World Health Organization play a central role in coordinating international research efforts, funding trials in lower-income countries, and ensuring equitable vaccine access. Moreover, collaborative research projects funded through multinational initiatives and philanthropic foundations like the Bill & Melinda Gates Foundation are helping bridge regional disparities and accelerate development timelines. These cross-sector and cross-border partnerships are vital in ensuring that vaccine research benefits from shared knowledge, resources, and global strategic alignment.

What Factors Are Driving Growth and Investment in the Vaccine Research Market?

The growth in the vaccine research market is driven by a convergence of public health needs, commercial opportunity, technological readiness, and global policy initiatives. One of the most prominent drivers is the increased frequency and severity of infectious disease outbreaks, which has created a sustained urgency for new vaccines that can be developed and deployed rapidly. Anticipation of future pandemics and the re-emergence of diseases once thought under control are prompting governments and global health organizations to invest in vaccine innovation as a critical component of national and international preparedness plans. At the same time, demographic trends such as aging populations, growing urbanization, and global travel are expanding the population vulnerable to infections, reinforcing the need for broader immunization strategies. The rising incidence of antimicrobial resistance has also intensified the search for preventive solutions like vaccines to reduce reliance on antibiotics. On the commercial side, the success of blockbuster vaccines has demonstrated the financial viability of vaccine R&D, attracting venture capital, pharmaceutical partnerships, and institutional funding into the sector. Technological advancements, such as the validation of mRNA platforms and scalable biomanufacturing techniques, have de-risked investment and encouraged rapid product development. Additionally, policy support in the form of fast-track regulatory pathways, advanced market commitments, and funding incentives is further stimulating innovation. These combined forces are creating a robust and rapidly expanding vaccine research market that is central not only to public health outcomes but also to the future of biomedical science and global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Vaccine Research market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Public Vaccine Research, Private Vaccine Research); Age Group (Pediatric Age Group, Adult Age Group)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AstraZeneca
  • Bavarian Nordic
  • BioNTech SE
  • Bharat Biotech
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vaccine Research - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Pandemic Preparedness Throws the Spotlight on Scalable and Rapid Vaccine Research Platforms
    • Surge in Government and Philanthropic Funding Spurs Acceleration of Early-Stage Vaccine Development
    • Here's How mRNA and Next-Gen Platform Technologies Are Transforming the Vaccine R&D Landscape
    • Increased Focus on Zoonotic and Emerging Pathogens Strengthens the Business Case for Broad-Spectrum Vaccine Candidates
    • Advancements in AI and Computational Biology Propel Growth in Antigen Discovery and Immunogenicity Prediction
    • Here's the Story: How Modular Clinical Trial Designs Are Streamlining Vaccine Research Timelines
    • Rising Demand for Universal and Multivalent Vaccines Expands the Scope of Multi-Pathogen Research Initiatives
    • Technological Progress in Adjuvants and Delivery Systems Enables Improved Efficacy and Dose Sparing
    • Growth in Oncology and Therapeutic Vaccines Opens New Avenues for Personalized Vaccine Research
    • Decentralized and Remote Trial Models Sustain Research Continuity Amid Global Health Disruptions
    • Equity and Global Access Considerations Drive Interest in Heat-Stable and Low-Cost Vaccine Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vaccine Research Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Public Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Private Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • JAPAN
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CHINA
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • EUROPE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • FRANCE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • GERMANY
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제